Joint Pain Injections Market Size, Share, Opportunities, And Trends By Product (Corticosteroid Injections, Hyaluronic Acid Injections, Platelet Rich Plasma Injections, Others), By Joint Type (Knee, Hip, Hand & Wrist, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Geography - Forecasts From 2025 To 2030

Description

Joint Pain Injections Market Size:

Joint Pain Injections Market is expected to grow at a 7.60% CAGR, achieving USD 8.814 billion by 2030 from USD 6.111 billion in 2025.

Key Market Highlights:

• Market expansion is driven by the rising incidence of musculoskeletal conditions and arthritis.
• The need for pain management injections is increased by the growing number of elderly people.
• Injections of hyaluronic acid and corticosteroids are currently the most common.
• Stem cell therapies and platelet-rich plasma (PRP) are becoming more sophisticated options.
• Increasing demand for less invasive methods of treating pain.

The Joint Pain Injections Market is going into an uptrend, the main reasons being the global rise of the diseases of arthritis, osteoarthritis, and other musculoskeletal disorders that influence people's mobility and the overall quality of their lives. Worldwide, as the number of old people grows, so does the need for good pain management solutions, hence the strong popularity of joint injections such as corticosteroids, hyaluronic acid, platelet-rich plasma (PRP), and stem cell therapies. The market gets a lot of good support from the rising preference for minimally invasive treatments, which allow the patient to have a faster recovery and, hence, are of longer-lasting use compared to oral medications or surgical interventions. The region of North America holds the lead mainly because of the well-developed healthcare infrastructure and the high rate of adoption of innovative therapies. On the other hand, the Asia-Pacific region is expected to have the quickest rise, with the opening of new hospitals, the growing awareness of health issues, and more patients. Besides, the breakthrough research in regenerative medicine and the large capital that pharmaceutical and biotechnology companies have put into the industry are the factors that keep the market on its upward trajectory, making joint pain injections a vital part of today's pain management and orthopedic care.

Joint pain injections, also referred to as intra-articular injections, are minimally invasive procedures where medication is injected directly into a joint to relieve pain and inflammation. These injections are commonly used for the treatment of various joint conditions, such as osteoarthritis, arthritis, rheumatoid arthritis, and some other inflammatory conditions affecting the joints. The minimally invasive nature of these injections makes them a favorable option for chronic pain management in the older population.

Key players working in the market include Sanofi, Seikagaku Corporation, Bioventus, Anika Therapeutics, Inc., Pacira BioSciences, Inc., Dr. Reddy’s Laboratories Ltd., Zimmer Biomet, Teva Pharmaceutical Industries Ltd., Ferring B.V., and GE Healthcare Limited.

Joint Pain Injections Market Trends

• Rising Adoption of Regenerative Therapies

A key aspect among the most significant is the Joint Pain Injections Market, which is better acknowledged as the trend towards the use of regenerative therapies, mainly the platelet-rich plasma (PRP) and stem cell-based injections. In comparison with the traditional corticosteroid and hyaluronic acid injections, which only temporarily relieve pain and reduce inflammation, regenerative therapies work on the patient's own body to provide tissue regeneration and, consequently, improvement of joint health in the long run. PRP injections, which are made from a patient’s own blood, contain high concentrations of growth factors that promote repair, and atrophy of the joint becomes slowed down, whereas stem cell therapies are very efficient in cartilage regeneration and have also helped to regain mobility of patients suffering from osteoarthritis and other degenerative diseases.

The increase in clinical evidence for the effectiveness of the treatments, along with patient requests for surgery alternatives and long-lasting drug use, is the reason behind the global quick acceptance. Besides that, the development of technology in cell therapy production, the increasing number of regulatory approvals, and the number of ongoing clinical trials have collectively contributed to the improvement in the availability of regenerative options. This trend is expected to overhaul the landscape of joint pain management, installing regenerative injections as a major driver of future growth.

Joint Pain Injections Market Drivers

• Obesity and a Sedentary Lifestyle

Around the world, 650 million adults are currently obese, and by 2025, the WHO predicts that 167 million adults and children will become less healthy owing to obesity. Obesity is a risk factor for joint diseases, as excessive weight places additional strain on the joints and increases the likelihood of joint dysfunction. Even in younger age groups, the prevalence of joint illnesses is rising due to the rising obesity rates around the world. Further, inactivity and sedentary behaviour are common features of contemporary living that can cause the muscles that support the joints to become weaker and increase the risk of developing joint illnesses.

• Rising Geriatric Population

According to the World Population Prospects 2022 report from the United Nations, the world's population will increase to about 8.5 billion in 2030 and reach 9.7 billion by 2050. The most prevalent type of arthritis, osteoarthritis, is characterized by the deterioration of joint cartilage, which causes pain, stiffness, and decreased mobility in the affected joints. The rising geriatric population translates to a higher prevalence of joint conditions that require interventions like joint pain injections.

Market Restraints

• High Cost and Limited Insurance Coverage

Injections for joint discomfort can be expensive, especially if several injections are needed over time. The type of injection, the medicine, and the healthcare practitioner can all affect the price. The price of injections may be a barrier to access for those with insufficient insurance or inadequate financial resources. Further, the cost of joint pain injections may not be entirely covered by insurance, depending on the type of injection and the individual's insurance coverage. Higher out-of-pocket costs for those seeking certain therapies may arise from this.

• Availability of Alternatives

There are several alternatives to joint pain injections that can be taken into consideration. These options comprise physical therapy that emphasizes exercises, stretches, and methods to strengthen muscles, increase joint mobility, and lessen discomfort. Additionally, oral medications, including paracetamol, analgesics, and nonsteroidal anti-inflammatory drugs (NSAIDs), might be recommended to treat joint pain and inflammation. These drugs frequently work in conjunction with other therapies to relieve mild to severe joint pain. Further, braces, splints, and canes are assistive devices that offer external support, and they can be especially beneficial for people who suffer from joint instability or osteoarthritis.

Market Opportunities

• Shift Toward Outpatient and Ambulatory Care Settings 

The Joint Pain Injections Market is moving toward outpatient clinics and ambulatory care centers substantially, increasingly as the need for less expensive, more accessible, and minimally invasive treatment options continues to escalate. Any kind of joint injections, such as corticosteroids, hyaluronic acid, PRP, or stem cell therapies, are normally simple and short in nature, thus can be done safely in any different hospital or even outside the hospital, meaning the reduction of both treatment costs and waiting times. The mentioned shift is being powered by the global trend in healthcare systems that are constantly focusing on cutting down the economic burden of chronic musculoskeletal diseases, as facilities for ambulatory care normally have fewer overhead costs than those for inpatient care. Accordingly, patients are in turn choosing these locations since they have shorter procedure times, can be discharged the same day, and have a lower risk of getting hospital-acquired infections. The injection procedure has been made more secure and accurate with the increased use of advanced imaging modalities, such as ultrasound-guided injections in ambulatory care settings. This has brought the confidence level of doctors and patients higher.

Joint Pain Injections Market Segmentation Analysis

• By Product

Based on the product, the market is classified into corticosteroid injections and hyaluronic acid injections. Platelet-rich plasma injections, and others.

By type, hyaluronic acid injections have gained a significant market share owing to the rising prevalence of osteoarthritis. The injections are intended to treat osteoarthritis-related pain and inflammation while increasing joint mobility. To treat joint discomfort, several companies have created hyaluronic acid injectable solutions. For instance, the hyaluronic acid injectable Euflexxa, made by Ferring Pharmaceuticals, is recognized for treating knee osteoarthritis. In those who are affected it tries to lessen discomfort and increase movement.

• By Joint Type

Based on joint type, the market is classified into knee, hip, hand & wrist, and others.

Based on joint type, the knees often require joint pain injections. Knee discomfort is a common complaint, particularly in elderly people and people who have diseases like osteoarthritis. The knee joint experiences a lot of stress and movement, which makes it more prone to deterioration. Hence, due to the high prevalence of knee pain, the share of joint pain injections for this market segment is anticipated to be the largest, leading to product launches by companies. For instance, in August 2021, Seikagaku Corporation introduced HyLink for the treatment of knee osteoarthritis in Taiwan.

Joint Pain Injections Market Regional Analysis

• By region, the market is segmented into North America, South America, the Middle East and Africa, and Asia-Pacific.

North America

North America holds a large market share owing to the rise in the number of chronic diseases, including osteoarthritis and rheumatoid arthritis. According to the American Autoimmune Related Diseases Association Inc., more than 50 million Americans are affected by autoimmune diseases. Further, by 2030, there will be 72 million instances of diagnosed arthritis cases in the United States, according to the Centers for Disease Control and Prevention. This is expected to increase the demand for joint pain injections in the region. Further, major pharmaceutical companies based in the U.S. are involved in the production of joint pain injections.

Europe

Growth in the European market is attributed to a well-established pharmaceutical sector and constant developments in countries like Germany, France, and Switzerland. Germany is renowned for having a robust pharmaceutical sector and an advanced healthcare system. Joint pain injections are among the many medicinal items that are produced by German pharmaceutical businesses.

Asia-Pacific

Asia has a sizable market for joint pain management due to its huge and aging population. The pharmaceutical industries of nations like India, China, South Korea, and Singapore have the potential to create a variety of drugs, including injections for joint pain. Apart from manufacturing hubs, Asia is also emerging as a pharmaceutical R&D hub, increasing investments in the development of innovative therapies, including joint pain.

South America

The Joint Pain Injections Market in South America has been experiencing gradual growth. The major factor contributing to this growth is the increasing prevalence of osteoarthritis and musculoskeletal disorders in the aging population of Brazil, Argentina, and Chile. As the largest healthcare market in the region, Brazil is responsible for most of the demand, driven by its rising orthopedic care facilities and a high number of patients who suffer from chronic joint conditions. An increase in healthcare spending, along with better access to private healthcare facilities, is fueling the use of joint pain injections like corticosteroids, hyaluronic acid, and PRP therapies. Besides this, the fast growth of medical tourism in Brazil and Argentina, especially for orthopedic and regenerative treatments, is a positive factor for the market. Nevertheless, some problems, such as limited reimbursement coverage, cost-sensitive patient groups, and unequal access between urban and rural areas, are obstacles.

The Middle East and Africa

The Joint Pain Injections Market in the Middle East and Africa is a developing area with increasing demand due to the rising prevalence of lifestyle-related joint disorders and the growing elderly population. Saudi Arabia, the UAE, and Qatar, the wealthier Gulf Cooperation Council (GCC) countries, are the most advanced adopters of pain management therapies. This trend is mainly due to the substantial investments made in healthcare modernization and the increasing number of private specialty clinics. Moreover, the demand for less invasive procedures such as joint injections has been growing because of more significant patient awareness of the availability of surgical alternatives and the expansion of health insurance coverage in metropolitan areas.

On the other hand, a major part of the African continent is still facing a lack of medical infrastructure, a shortage of qualified orthopedic specialists, and low purchasing power, resulting in limited use of these areas.

Joint Pain Injections Market Competitive Landscape

• Key Industry Players

The Joint Pain Injections Market is a sector with tight competition that is characterized by the participation of big multinational pharmaceutical and biotechnology leaders. The major players, such as Sanofi, Seikagaku Corporation, Bioventus, Anika Therapeutics, Inc., Pacira BioSciences, Inc., Dr. Reddy’s Laboratories Ltd., Zimmer Biomet, Teva Pharmaceutical Industries Ltd., Ferring B.V., and GE Healthcare Limited, are vigorously promoting innovation through such activities as new product development, corporate strategy, and the use of regenerative therapies. These companies are first of all engaged in developing products in corticosteroids, hyaluronic acid, PRP, and stem cell-based injections. Besides that, they are using their worldwide distribution networks, which are the two factors that attract more customers to the market. Their initiatives in efficacy improvement, safety certification, and accessibility enhancement are the reasons why they hold a strong position in the rivalry of the joint pain injection industry. 

List of Key Company Profiled:

• Sanofi
• Seikagaku Corporation
• Bioventus
• Anika Therapeutics, Inc.
• Pacira BioSciences, Inc.
• Dr. Reddy’s Laboratories Ltd.
• Zimmer Biomet
• Teva Pharmaceutical Industries Ltd.
• Ferring B.V.
• GE Healthcare Limited

Joint Pain Injections Market Key Developments

• Research and Development: In April 2025, Pacira BioSciences, Inc. reported new data showing that PCRX-201 (enekinragene inzadenovec), a locally administered gene therapy candidate, improved knee pain, stiffness, and function for up to two years after a single local administration in patients with mild, moderate, and severe osteoarthritis of the knee.        
• Collaboration: In February 2025, SELARSD (ustekinumab-aekn) injection, a biosimilar to Stelara® (ustekinumab), is now available in the United States for the treatment of psoriatic arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, pediatric plaque psoriasis, and pediatric psoriatic arthritis, according to a statement released by Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and Alvotech. As a result of the strategic alliance between Teva and Alvotech, this is the second biosimilar currently offered on the American market.  
• Expansion: In February 2025, A significant turning point in Contura Orthopedics' international growth was the announcement of Contura Orthopedics (Canada) Ltd. Following Health Canada's 2024 approval of Arthrosamid®, patients in North America who suffer from osteoarthritis (OA)-related knee pain can now access this innovative hydrogel injection.   

Segmentation:

• BY PRODUCT
  • Corticosteroid Injections
  • Hyaluronic Acid Injections
  • Platelet Rich Plasma Injections
  • Others
• BY JOINT TYPE
  • Knee
  • Hip
  • Hand & Wrist
  • Others
• BY DISTRIBUTION CHANNEL
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• BY GEOGRAPHY
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • The Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others

Table Of Contents

1.  INTRODUCTION

1.1.  Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Research Process 

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. JOINT PAIN INJECTIONS MARKET, BY PRODUCT

5.1. Introduction

5.2. Corticosteroid Injections

5.3. Hyaluronic Acid Injections

5.4. Platelet Rich Plasma Injections

5.5. Others

6. JOINT PAIN INJECTIONS MARKET, BY JOINT TYPE

6.1. Introduction

6.2. Knee

6.3. Hip

6.4. Hand & Wrist

6.5. Others

7. JOINT PAIN INJECTIONS MARKET, BY DISTRIBUTION CHANNEL

7.1. Introduction

7.2. Hospital Pharmacies

7.3. Retail Pharmacies

7.4. Online Pharmacies

8. JOINT PAIN INJECTIONS MARKET, BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. The Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

10. COMPANY PROFILES

10.1. Sanofi

10.2. Seikagaku Corporation

10.3. Bioventus

10.4. Anika Therapeutics, Inc.

10.5. Pacira BioSciences, Inc.

10.6. Dr. Reddy’s Laboratries Ltd.

10.7. Zimmer Biomet

10.8. Teva Pharmaceutical Industries Ltd.

10.9. Ferring B.V.

10.10. GE Healthcare Limited

Companies Profiled

Sanofi

Seikagaku Corporation

Bioventus

Anika Therapeutics, Inc.

Pacira BioSciences, Inc.

Dr. Reddy’s Laboratries Ltd.

Zimmer Biomet

Teva Pharmaceutical Industries Ltd.

Ferring B.V.

GE Healthcare Limited

Related Reports